Sorrento Therapeutics (SRNE) Phase Ib Study of anti-CEA CAR-T Shows Promising Clinical Activity and Safety – StreetInsider.com
|
Sorrento Therapeutics (SRNE) Phase Ib Study of anti-CEA CAR–T Shows Promising Clinical Activity and Safety
StreetInsider.com Two patients were withdrawn, one for disease progression prior to CAR-T infusion and another for biliary obstruction due to centrally located disease. Subjects received three HAI of anti-CEA CAR–T cells (1e10 cells per dose) along with a low dose IL-2 … |
